Toripalimab, sold under the brand name Loqtorzi, is a monoclonal antibody used for the treatment of melanoma and nasopharyngeal carcinoma. Toripalimab is a recombinant humanized programmed cell death protein 1 (PD-1) monoclonal antibody that acts as a checkpoint inhibitor.\u00a0In 2018, toripalimab was approved in China for the treatment of unresectable or metastatic melanoma that has failed previous systemic therapy.] In October 2023, the US Food and Drug Administration (FDA) approved toripalimab for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma when used with cisplatin and gemcitabine.<\/p>\n
If LOQTORZI (toripalimab-tpzi) injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
Note:<\/strong><\/em> NEWS \/ UPDATES<\/strong><\/p>\n Loqtorzi is used\u00a0to treat certain types of nasopharyngeal cancer (NPC) in adults<\/b>. It may be prescribed as a first treatment when NPC has spread or come back. This means it must have spread or come back in other parts of your body near the throat.<\/p>\n Source Details: Patient Information<\/a><\/p>\n IPN, New Delhi can facilitate patient to import of “LOQTORZI (toripalimab-tpzi) injection”<\/strong> in small quantities for personal use. For this applicant is required to make an application in Form 12A, along with the prescription of the Registered Medical Practitioner (RMP). If you have any question, please\u00a0email IPN healthcare Support Team <\/a>for LOQTORZI (toripalimab-tpzi) injection<\/strong> price list or cost in India. on Mr. Tarun:- +91 9891 296 838 \/ Mr. Neeraj:- +91 9811 747 774.<\/strong><\/em><\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/em><\/p>\n\n
LOQTORZI (toripalimab-tpzi) injection, for intravenous use Initial U.S. Approval: 2023<\/h2>\n
\n\n
\n Brand Name:<\/strong><\/td>\n LOQTORZI<\/td>\n<\/tr>\n \n Generic Name:<\/strong><\/td>\n toripalimab-tpzi<\/td>\n<\/tr>\n \n Strength:<\/strong><\/td>\n Injection: 240 mg\/6 mL (40 mg\/mL) solution in a single-dose vial<\/td>\n<\/tr>\n \n Manufacturer:<\/strong><\/td>\n Coherus BioSciences, Inc.<\/td>\n<\/tr>\n \n Approved By:<\/strong><\/td>\n EMA, USFDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n